Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
News, developments and strategies related to eClinical, data management, data collection, ePRO, and more information technology used in the drug development chain. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
|
See our 2012 Buyers Guide Digital Edition.
 
|
New Paper in Cell Highlights the Potential Role of TB-403 (Anti-PlGF) in the Treatment of Medulloblastoma, a Pediatric Brain Tumor
Publish date: Feb 28, 2013
PR Newswire LEUVEN, Belgium, February 28, 2013 LEUVEN, Belgium, February 28, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), and co-development partner BioInvent International AB (OMXS: BINV), announce
today the publication of a paper in the prestigious journal Cell, highlighting the potential of TB-403 to improve the
treatment of medulloblastoma, the most common brain tumor in children. The Cell publication highlights for the first time a new mechanism of action, showing that PlGF plays a vital role
in the brain and that its expression is required for the growth and spread of medulloblastoma. The novel positive findings in this paper provide evidence that could warrant further development of TB-403 as one of the
first targeted therapies to treat this childhood cancer. TB-403 is a monoclonal antibody against placental growth factor (PlGF).
PIGF is a naturally occurring protein that belongs to the family of vascular endothelial growth factors (VEGF) that promote
the formation of blood vessels. TB-403 was in-licensed by ThromboGenics from the Flanders Institute for Biotechnology (VIB), where the therapeutic potential
of anti-PlGF agents to treat cancer was first developed by Prof. Peter Carmeliet at the University
of Leuven, Belgium. This Cell paper is reporting the findings of new pre-clinical research performed at the Massachusetts General Hospital
in Harvard (Boston), in collaboration with the team of Prof Peter Carmeliet. With an emerging ophthalmologic franchise, Thrombogenics is also evaluating the role of TB-403 for ophthalmic indications. About ThromboGenics ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic
medicines. The Company's lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment
of symptomatic VMA and was launched in January 2013. In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the
commercialization of JETREA® outside the United States. Under this agreement,
ThromboGenics could receive up to a total of €375 million in up-front and milestone payments. It will receive significant
royalties from Alcon's net sales of JETREA®
. ThromboGenics and Alcon intend to share the costs equally of developing JETREA® for a number of new
vitreoretinal indications. The JETREA European Marketing Authorisation Application is currently under review by the European Medicines Agency. Following
the positive CHMP recommendation, a final decision by the European Commission on European approval is expected in the first
half of 2013. ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), formerly referred to as TB-403, for the treatment
of ophthalmic indications. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin,
NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange
under the symbol THR. More information is available at http://www.thrombogenics.com. About BioInvent BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company focused
on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes
three product candidates for the treatment of cancer. The company's competitive position is underpinned by n-CoDeR®, a proprietary antibody development platform.
The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance
the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners
include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at http://www.bioinvent.com. Important information about forward-looking statements Certain statements in this press release may be considered "forward-looking". Such forward-looking
statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties.
The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume
an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or
any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that
could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.
This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics
in any jurisdiction. No securities of ThromboGenics may be offered or sold within the
United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption
therefrom, and in accordance with any applicable U.S. state securities laws.
For further information please contact: ThromboGenics:
Wouter Piepers, Global Head of Corporate Communications Dr. Patrik De Haes, CEO
Chris Buyse, CFO BioInvent International AB:
Cristina Glad, D.Sc., President & CEO Citigate Dewe Rogerson
David Dible/ Nina Enegren/ Sita Shah
The Trout Group (US investor relations)
Todd James/ Simon Harnest
SOURCE ThromboGenics NV
|
|
|
|
|
Facebook
Quizzes
